Exenatide and Parkinson’s
The Exenatide-PD3 study was a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon) which finished in early 2024. The results of this trial have now been published and they indicate that the study did not slow the progression of Parkinson’s compared to...
Ambroxol for Parkinson’s
ASPro-PD, or “Ambroxol to Slow Progression in Parkinson’s”, is a phase 3 clinical trial looking to assess whether ambroxol, a cough medicine, can slow or stop the progression of Parkinson’s motor symptoms. Contents About the study Led by Professor Anthony Schapira at University College London...
UDCA for Parkinson’s
The UP Study, or UDCA for Parkinson’s Study, was a phase 2 clinical trial which aimed to assess the safety and tolerability of ursodeoxycholic acid (UDCA) in people with Parkinson’s. Contents About the study Led by Professor Oliver Bandmann at the University of Sheffield, this...